Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

Literature DB >> 27612280

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

Pedro Barata¹, Anil K Sood², David S Hong³.

Abstract

Recent advances in RNA delivery and target selection provide unprecedented opportunities for cancer treatment, especially for cancers that are particularly hard to treat with existing drugs. Small interfering RNAs, microRNAs, and antisense oligonucleotides are the most widely used strategies for silencing gene expression. In this review, we summarize how these approaches were used to develop drugs targeting RNA in human cells. Then, we review the current state of clinical trials of these agents for different types of cancer and outcomes from published data. Finally, we discuss lessons learned from completed studies and future directions for this class of drugs.

Entities: Disease Species

Keywords: Antisense oligonucleotides; Cancer clinical trials; RNA therapeutics; miRNA; siRNA

Mesh：

Substances：

Year: 2016 PMID： 27612280 DOI： 10.1016/j.ctrv.2016.08.004

Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111

Keyword Cloud
Cited

47 in total

1. Clinical Cancer Nanomedicine.

Authors: Joy Wolfram; Mauro Ferrari
Journal: Nano Today Date: 2019-03-06 Impact factor: 20.722

Review 2. Epidrugs: targeting epigenetic marks in cancer treatment.

Authors: Cristiana Libardi Miranda Furtado; Maria Claudia Dos Santos Luciano; Renan Da Silva Santos; Gilvan Pessoa Furtado; Manoel Odorico Moraes; Claudia Pessoa
Journal: Epigenetics Date: 2019-07-13 Impact factor: 4.528

Review 3. Biomedical potential of mammalian spectraplakin proteins: Progress and prospect.

Authors: Sarah A King; Han Liu; Xiaoyang Wu
Journal: Exp Biol Med (Maywood) Date: 2019-08-09

4. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

Authors: Yazhe Wang; Ying Xie; Kameron V Kilchrist; Jing Li; Craig L Duvall; David Oupický
Journal: ACS Appl Mater Interfaces Date: 2020-01-15 Impact factor: 9.229

Review 5. Targeting RNA in mammalian systems with small molecules.

Authors: Anita Donlic; Amanda E Hargrove
Journal: Wiley Interdiscip Rev RNA Date: 2018-05-03 Impact factor: 9.957

6. Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents.

Authors: Rajendran J C Bose; Sukumar Uday Kumar; Yitian Zeng; Rayhaneh Afjei; Elise Robinson; Kenneth Lau; Abel Bermudez; Frezghi Habte; Sharon J Pitteri; Robert Sinclair; Juergen K Willmann; Tarik F Massoud; Sanjiv S Gambhir; Ramasamy Paulmurugan
Journal: ACS Nano Date: 2018-10-22 Impact factor: 15.881

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.

1. Clinical Cancer Nanomedicine.

Review 2. Epidrugs: targeting epigenetic marks in cancer treatment.

Review 3. Biomedical potential of mammalian spectraplakin proteins: Progress and prospect.

4. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.

Review 5. Targeting RNA in mammalian systems with small molecules.

6. Tumor Cell-Derived Extracellular Vesicle-Coated Nanocarriers: An Efficient Theranostic Platform for the Cancer-Specific Delivery of Anti-miR-21 and Imaging Agents.

7. Identification and Characterization of New RNA Tetraloop Sequence Families.

8. M³RNA Drives Targeted Gene Delivery in Acute Myocardial Infarction.

9. Contribution of 3'T and 3'TT overhangs to the thermodynamic stability of model siRNA duplexes.

10. Efficient Synthesis of Light-Triggered Circular Antisense Oligonucleotides Targeting Cellular Protein Expression.